Similar articles

• Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.

  Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A. Sasada T, et al. Am J Clin Oncol. 2008 Feb;31(1):71-8. doi: 10.1097/COC.0b013e31807a328c. Am J Clin Oncol. 2008. PMID: 18376231
• Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?

  Ajani JA. Ajani JA. Nat Clin Pract Oncol. 2008 Sep;5(9):508-9. doi: 10.1038/ncponc1200. Epub 2008 Jul 15. Nat Clin Pract Oncol. 2008. PMID: 18628737
• Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy.

  Tanaka K, Mohri Y, Ohi M, Yokoe T, Koike Y, Morimoto Y, Miki C, Tonouchi H, Kusunoki M. Tanaka K, et al. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8. Clin Oncol (R Coll Radiol). 2008. PMID: 18691855
• Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.

  Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI. Jung JY, et al. Oncol Rep. 2009 Feb;21(2):523-9. Oncol Rep. 2009. PMID: 19148531 Clinical Trial.
• [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].

  Bardet E, Bourhis J, Cals L, Fayette J, Guigay J, Hans S, Saint-Guily JL, Lagarde F, Lallemant B, Milano G, Rolland F, Lefebvre JL. Bardet E, et al. Bull Cancer. 2009 Oct;96(10):1013-28. doi: 10.1684/bdc.2009.0951. Bull Cancer. 2009. PMID: 19744919 French.